IFN gamma is a pro-inflammatory cytokine secreted by T and NK cells in response to viral infection and or inflammatory conditions. IFN gamma plays a major role in innate and adaptive immunity by promoting T cell differentiation into TH1 and development of Treg, as well as by inhibiting T cell differentiation into TH17. Its anti-tumor properties have been used in treatment of osteoporosis and it is of great interest in immuno-oncology where it improves survival in patients with bladder or ovarian carcinoma.

Assessment of serum samples often requires enhanced sensitivity. In some cases, AlphaLISA assays may have sufficient sensitivity to enable detection of low levels of analytes in serum or plasma.

At Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.